Células-Tronco para Parkinson no Japão: TUDO Sobre a Aprovação (2026)

🧠 Has Japan approved the first iPS stem cell therapy for Parkinson's Disease? Discover the truth behind the headlines in this video! We thoroughly analyze the first clinical trial from Kyoto University, published in the journal Nature (2025), and the recent conditional approval by the Japanese regulatory body (PMDA) in March 2026 for the drug Achempre. Understand how dopamine replacement works in the brain, the limitations of levodopa, the real risks, and why this new treatment is not yet available in Brazil or the rest of the world. In this video, we avoid sensationalism and translate the real science for you. Understand what this 7-year approval means in practice and what the next steps are for evidence-based medicine in the treatment of neurodegenerative diseases. 🕒 TIMESTAMPS: 00:00 - Introduction: The first treatment in Japan 01:05 - How does Parkinson's Disease work? 02:20 - The problem with standard treatment (Levodopa) 03:30 - iPS Stem Cells: The "Reset" button 06:05 - How was the Kyoto University study conducted? 07:20 - Real results: Efficacy vs. Placebo Effect 09:35 - Risks, Limitations, and Conflicts of Interest 12:05 - The truth about the "Approval" in Japan 14:25 - Conclusions: Are we close to a cure? --- 📚 SCIENTIFIC SOURCES AND REFERENCES MENTIONED: Kikuchi, T., et al. (including Jun Takahashi). (2025). Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease. Nature, 641(8064), 971-977. https://doi.org/10.1038/s41586-025-08... --- 🔔 DID YOU LIKE THE CONTENT? Subscribe to the Neuroepifania channel:    / @neuroepifanias   Leave your like, comment with your questions and share with colleagues! 🔗 CONNECT WITH NEUROEPIFANIA: Instagram: https://www.instagram.com/accounts/lo... Website/Blog https://drthiagoguimaraesneuro.com/ --- ** IMPORTANT MEDICAL LEGAL NOTICE ** The information contained in this video is for educational and informational purposes only. It is not intended to replace professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare professional regarding any questions you may have concerning a medical condition. Reliance on any information provided by this video/channel is solely at your own risk. The "neuroepifania" channel disclaims all liability for any damages arising directly or indirectly from any use of the Video Content. This content does not establish a doctor-patient relationship. ------------------------------------------------------------------------------------------------------------------------ Thiago Gonçalves Guimarães Neurologist at the Hospital das Clínicas of the Faculty of Medicine of USP (HC-FMUSP) Subspecialist in Movement Disorders and Neurogenetics at HC-FMUSP. CRM: 178.347 #Parkinson, #StemCells, #Neuroscience, #Japan, #Neurology, #Health, #Medicine, #Parkinson'sDisease, #Science, #Neuroepifania